Ara
Toplam kayıt 5, listelenen: 1-5
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
(Akad Doktorlar Yayınevi, 2012)
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ...
Idelalisib At The Crossroads Of B-Cell Lymphoproliferative Disorders
(Akad Doktorlar Yayınevi, 2016)
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of the delta isoform of PI3K, ...
Generic Imatinib Mesylate Is As Effective As Original Glivec In The Clinical Management Of Cml
(Akad Doktorlar Yayınevi, 2015)
Unsustainable drug prices in chronic myeloid leukemia (CML) and cancer may be causing harm to patients. The aim of this multi-center study is to assess the efficacy of generic imatinib mesylate (IM) over Glivec in terms ...
Safety and Efficacy of Ankaferd Hemostat (Abs) in the Chemotherapy-Induced Oral Mucositis
(Akad Doktorlar Yayınevi, 2015)
Oral mucositis, characterized by ulcerative lesions in the oral mucosa of patients undergoing chemotherapy, is currently considered to be the most severe complication of anti-cancer therapy which is affecting 40-80% of ...